Article Text


Elevated incidence rates of diabetes in Peru: report from PERUDIAB, a national urban population-based longitudinal study


Objective A recent report from a non-nationally representative, geographically diverse sample in four separate communities in Peru suggests an unusually high diabetes incidence. We aimed to estimate the national diabetes incidence rate using PERUDIAB, a probabilistic, national urban population-based longitudinal study.

Research design and methods 662 subjects without diabetes, selected by multistage, cluster, random sampling of households, representing the 24 administrative and the 3 (coast, highlands and jungle) natural regions across the country, from both sexes, aged 25+ years at baseline, enrolled in 2010–2012, were followed for 3.8 years. New diabetes cases were defined as fasting blood glucose ≥126 mg/dL or on medical diabetes treatment.

Results There were 49 cases of diabetes in 2408 person-years follow-up. The weighted cumulative incidence of diabetes was 7.2% while the weighted incidence rate was estimated at 19.5 (95% CI 13.9 to 28.3) new cases per 1000 person-years. Older age, obesity and technical or higher education were statistically associated with the incidence of diabetes.

Conclusion Our results confirm that the incidence of diabetes in Peru is among the highest reported globally. The fast economic growth in the last 20 years, high overweight and obesity rates may have triggered this phenomenon.

  • incidence
  • population-based studies

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

Statistics from


  • Contributors SNS, MER, AJA and CAM conceptualized and designed the study, contributed to the interpretation of the results, were involved in critical revisions, and have read and approved the final manuscript. SNS and MER reviewed the statistical analyses. SNS is the guarantor of this work.

  • Funding This work was funded by Sanofi Aventis del Perú S.A

  • Competing interests SNS has received honoraria from Sanofi for participation in this study. He also provided ad hoc consultancy to Novo Nordisk. CM is a employee of Sanofi Perú

  • Patient consent Obtained.

  • Ethics approval Ethics Committee of San Martin de Porres University, Lima, Peru.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.